Upcoming Webinars and Trainings (updated Dec 6)

These seminars are provided by Qiagen (not BTEP) and are linked here for your convenience.

  • Dec 7 @ 11AM, Putting the Pieces Together, from Variant Calling to Biological Insights – A Lynch Syndrome Case Study
           Register here

In this webinar, we present a case study on Lynch syndrome (LS), a hereditary condition characterized by a high risk of colorectal cancer, endometrial cancer, and other neoplasia that typically manifests in the context of germline variants in DNA mismatched genes.
To study whether other germline pathogenic variants of hereditary cancer genes are present in patients previously diagnosed with LS, the researchers analyzed a comprehensive panel of cancer-predisposing genes by NGS among 84 LS probands.

With this study as an example, we will illustrate how you can use your own data and public data to conduct translational research using 3 software solutions from QIAGEN.

This webinar will focus on the following elements:

  • Data analysis – How you can efficiently retrieve and process FASTQ data with accurate variant interpretation using CLC Genomics Workbench
  • Interpretation – How you can take a set of variants and rapidly assess sample variants for disease relevance and pathogenicity using QCI Interpret Translational
  • Discovery – How you can combine results and contextualize variant biomarkers with other public datasets using QIAGEN Ingenuity Pathway Analysis (IPA)

Speaker:

Eric Seiser, PhD
Senior Field Applications Scientist
QIAGEN Digital Insights

Dr. Eric Seiser is a Senior Field Applications Scientist with QIAGEN Digital Insights. Eric has a Master’s degree in bioinformatics and a PhD in functional genomics. His previous research focused on pediatric cancer biology at the Children’s Hospital of Philadelphia, the comparative oncology of genomic alterations in dog cancers at NC State University, and cancer pharmacogenetics at UNC.

 

  • Dec 7 @1 PM, New user training: Large dataset analysis and knowledge base queries using QIAGEN Ingenuity Pathway Analysis (IPA)

          Register here

Join us for a 90-minute training session for new users of QIAGEN IPA.

Users will learn how to:
• Upload their dataset (RNA-seq, scRNA-seq, proteomics, metabolomics and more) and perform interactive core/pathway analysis in IPA
• Understand the different result types produced (pathways, key regulators, impact on biological functions/diseases and more)
• Compare different experimental conditions (treatments, timepoints, single-cell clusters, disease types and more) and identify similarities and contrasts
• Generate a network even without a dataset or experimental design for hypothesis generation

 

  • Dec 8 @ 1 PM, QIAGEN IPA deep-dive and new features training
    Register here

As requested by many users, your QIAGEN Digital Insights team is excited to introduce QIAGEN Ingenuity Pathway Analysis (IPA) deep-dive trainings. In these three-hour training sessions, we will discuss the following topics:

Part 1: Deep dive into QIAGEN IPA core and comparison analyses

Part 2: Deeper dive into how to use QIAGEN IPA even without user data

Agenda: https://qiagen.showpad.com/share/a3C2w9D6U58SJdlTAKXDj

Offered on the 1st Wednesday of every month at 1:00 PM ET/ 10:00 AM PT (unless it falls on a US holiday)

 

  • Dec 9 @ 1PM, Systems Analysis of Cell Therapies: Demonstrating QIAGEN Ingenuity Pathway Analysis and QIAGEN Omicsoft on CAR-Ts and T-Cell Exhaustion
           Register here

Cell-based therapies are emerging as a promising strategy for cancer, autoimmune and various diseases. Cell-based therapies such as tumor-infiltrating lymphocyte (TIL), T-cell receptor (TCR)-based, CAR T cell, Natural killer (NK) cell therapies continue to evolve in their use for treating human diseases. QIAGEN database uses millions of curated literature findings in the QIAGEN/ IPA knowledgebase and the OmicSoft digital warehouse which has been used by both biopharma and academic investigators to do novel discoveries in cell based therapeutic area.

In this training, we will explore how to:

• Understand functional mechanisms and underlying signaling pathways
• Explore the regulatory framework of disease and causal networks
• Rationalize markers by automated comparison with public data sets
• Profile phenotypic effects and markers for T-cell exhaustion, cytokine release syndrome, neuro-toxicities etc.
• Identify biomarker signatures of efficacy

 

  • Dec 10 @ 11AM, How community hospital labs can perform comprehensive genomic profiling with the support of professional clinical interpretation services
           Register here

As next-generation DNA sequencing technology continues to evolve and become further integrated into routine clinical testing, the need for efficient and accurate clinical interpretation of oncology diagnostic tests becomes even more pressing—especially among community hospital labs.

Standard sequencing panels are growing, drugs are covering more targets and pathways, and the expansion of the scientific and clinical literature has become exponential, presenting a significant challenge to laboratory directors and clinicians who need to understand the implications of the test results. Further, the implications of mutations can be applicable across many cancer types, but often are different based on the specific cancer type.

In this webinar, we will discuss how community hospital labs can perform comprehensive genomic profiling faster and with greater accuracy and confidence using QIAGEN’s professional clinical interpretation services: QCI Precision Insights.

Attendees will learn:

  • About the world-class team of molecular biologists and oncologists that power QCI Precision Insights
  • How community hospital labs can get up-to-date and detailed disease-specific clinical insights and therapeutic options for each patient within minutes
  • About use-cases and examples of clinical annotation in different diseases of varying specificity

Speakers: 

Sheryl Elkin, PhD
Chief Scientific Officer
N-of-One, a QIAGEN company

Sheryl Krevsky Elkin, PhD, is the Chief Scientific Officer at N-of-One, a QIAGEN company. An early member of the N-of-One team, Dr. Elkin has led the interpretation of thousands of patient cases, establishing a rigorous process for the analysis of scientific and clinical evidence and presentation of molecular and clinical evidence to physicians to help guide their therapeutic decisions. Dr. Elkin has taken a lead role in the development of the N-of-One clinical interpretation methodology to support clinicians in identifying therapeutic strategies specific to each patient. Prior to joining N-of-One, Dr. Elkin completed her postdoctoral fellowship at the Massachusetts Institute of Technology’s Center for Cancer Research, where she earned a fellowship from the Leukemia and Lymphoma Society. She earned her doctorate in Biological and Biomedical Sciences from Harvard Medical School and an A.B. in Biology and Music from Amherst College, graduating Phi Beta Kappa and summa cum laude, with High Distinction in Biology.

Linda Call, Ph.D.
Director of Scientific and Clinical Operations
QIAGEN Digital Insight

Linda Call, PhD, is the Director of Scientific and Clinical Operations for Precision Insights products at QIAGEN Digital Insights. Dr. Call joined QIAGEN through the acquisition of N-of-One, and her operations experience has facilitated increased automation, implementation of strategic preparation and standardization, and incorporation of feedback from key stakeholders to significantly streamline the workload, reduce costs and improve our client experience. Dr. Call played a significant role in the development of the N-of-One clinical interpretation methodology that supports clinicians in identifying therapeutic strategies for patients. Prior to joining N-of-One, Dr. Call completed a postdoctoral research fellowship and a Clinical Cytogenetics fellowship at Harvard Medical School. She earned her doctorate in Human Genetics from The Johns Hopkins University and a B.S. in Biology from the Massachusetts Institute of Technology.

 

  • Dec 15 @ 11AM, Overcoming Challenges of Copy Number Variant Interpretation with QCI Interpret and the ACMG Guidelines for CNVs
           Register here

Copy number variant (CNV) analysis has been part of clinical diagnostics for almost two decades. With the evolution of genomic technologies for CNV detection, we have learned that CNVs can range in size from tens of bases to megabases and are an important source of both normal and pathogenic genomic variation. However, CNV interpretation requires collecting and evaluating multiple types of evidence from many sources, which has posed challenges for consistent, high quality clinical interpretation of CNVs.

In this webinar, we will introduce a genomic variant analysis, interpretation and reporting solution that is being used by major labs and population health programs around the world. QCI Interpret is clinical decision support software that accelerates variant interpretation and reporting by automating curation workflows, dynamically computing variant classifications according to professional guidelines, and generating customized, patient-specific reports. The recent update of QCI Interpret further supports the interpretation and reporting of CNVs. Over 60,000 expert-curated CNV literature references have been added to QCI Interpret that the software can use among other evidence for interpretation, including generating auto-classifications of CNV pathogenicity with full transparency using the new ACMG/ClinGen CNV guidelines for hereditary workflows.

Attend this webinar, and you will learn:

  • About the new CNV features and content in QCI Interpret, including how the software computes CNV pathogenicity and improves handling of CNVs and splice variants at the imprecise exon- and precise breakpoint-levels
  • How QCI Interpret helps you quickly evaluate your CNVs to determine if same/similar CNVs have been observed in clinical cases or as common genetic variants
  • How QCI Interpret has new CNV classification functionalities following the new ACMG/ClinGen guidelines for the interpretation and reporting of constitutional CNVs

Speakers: 

Martin Jones, Ph.D.
Scientific Product Owner
QIAGEN Digital Insights

Dr. Martin Jones is the Global Product Owner for clinical decision support software and interpretation services at QIAGEN Digital Insights. He is a precision oncology expert with extensive experience in clinically applied and cohort multi-omic analysis with a strong background in personalized medicine and functional genomics. Prior to joining QIAGEN, Dr. Jones led the clinical interpretation and communication team at the Michael Smith Genome Sciences Centre in Canada. In this role, Dr. Jones was responsible for personalized oncogenomics, as well as providing the genomic analysis of metastatic disease, including whole genome sequencing, tumor/normal, RNAseg tumor- and oncology-specific panels. Dr. Jones earned his Ph.D. in molecular biology and biochemistry from the Simon Fraser University in Canada and was a post-doctoral fellow at the University of British Columbia.

Dan Richards, Ph.D.
Vice President, Global Clinical Product Management
QIAGEN Digital Insights

Dr. Dan Richards is Vice President, Global Clinical Product Management, Digital Insights at QIAGEN where he focuses on the automated interpretation of molecular variation in the context of current clinical evidence. Dan earned his Ph.D. in human Genetics from Stanford University and co-founded Ingenuity Systems whose analysis applications and manually curated knowledge base of peer-reviewed scientific evidence are used by scientists worldwide to interpret genomic data in the context of current biomedical knowledge.